355391-05-8

Basic information

• Product Name: 4-(cyclopropylmethoxy)benzoic acid
• Synonyms: 4-(cyclopropylmethoxy)benzoic acid
• CAS NO: 355391-05-8
• Molecular Formula: C₁₁H₁₂O₃
• Molecular Weight: 192.21118
• Mol File: 355391-05-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(cyclopropylmethoxy)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(cyclopropylmethoxy)benzoic acid(355391-05-8)
• EPA Substance Registry System: 4-(cyclopropylmethoxy)benzoic acid(355391-05-8)

Safety Data

• Hazardous Substances Data: 355391-05-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(cyclopropylmethoxy)benzoic acid is used as an intermediate in the synthesis of various drugs and active pharmaceutical ingredients, contributing to the development of new medications and therapies.
Used in Anti-inflammatory Applications:
4-(cyclopropylmethoxy)benzoic acid is studied for its potential anti-inflammatory properties, which could be utilized in the treatment of inflammation-related conditions and diseases.
Used in Antibacterial Applications:
4-(cyclopropylmethoxy)benzoic acid is also investigated for its potential antibacterial properties, which could be employed in the development of new antibiotics to combat bacterial infections.
Used in Disease Treatment Research:
4-(cyclopropylmethoxy)benzoic acid has been explored for its potential role in the treatment of various diseases and conditions, making it a compound of interest for further research and development in the medical field.

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 7051-34-5 cyclopropylcarbinyl bromide 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 1370698-59-1 C₂₈H₃₀F₂N₄O₂ 
• 1370698-67-1 C₁₈H₁₉ClN₂O₂ 
• 1443367-26-7 ethyl 8-(4-(cyclopropylmethoxy)benzamido)-4-oxo-4H-chromene-2-carboxylate 
• 1443367-30-3 8-(4-(cyclopropylmethoxy)benzamido)-4-oxo-4H-chromene-2-carboxylic acid 
• 1431532-81-8 tert-butyl ((2S)-1-(3-((4-(cyclopropylmethoxy)benzoyl)amino)-4-nitrophenoxy)propan-2-yl)carbamate 
• 1431534-08-5 N-(5-(benzyloxy)-3-bromopyridin-2-yl)-4-(cyclopropylmethoxy)benzamide 
• 1431532-96-5 tert-butyl ((2S)-1-((4-chloro-5-((4-(cyclopropylmethoxy)benzoyl)amino)pyridin-2-yl)oxy)propan-2-yl)carbamate 
• 1431535-52-2 N-(2-(benzyloxy)-5-hydroxypyridin-4-yl)-4-(cyclopropylmethoxy)benzamide 
• 1431533-84-4 tert-butyl 4-((4-(cyclopropylmethoxy)benzoyl)amino)-3-hydroxypiperidine-1-carboxylate 
• 1431534-15-4 2-ethylhexyl 3-((2-(((2S)-2-acetamidopropyl)oxy)-5-((4-(cyclopropylmethoxy)benzoyl)amino)pyridin-4-yl)sulfanyl)propanoate 
• 1431533-08-2 4-(cyclopropylmethoxy)-N-(4,6-dichloropyridin-3-yl)benzamide 
• 1467081-09-9 tert-butyl ((2S)-1-((2-(4-(cyclopropylmethoxy)phenyl)[1,3]oxazolo[5,4-c]pyridin-6-yl)oxy)propan-2-yl)carbamate 
• 1431535-54-4 6-(benzyloxy)-2-(4-(cyclopropylmethoxy)phenyl) [1,3]oxazolo[5,4-c]pyridine 
• 1314128-69-2 ethyl 6-[({4-(cyclopropylmethoxy)phenyl}carbonyl)amino]-1,7-dimethyl-1H-indole-2-carboxylate 

Relevant articles and documents

Stepwise benzylic oxygenation via uranyl-photocatalysis

Stepwise oxygenation at the benzylic position (1°, 2°, 3°) of aromatic molecules was comprehensively established under ambient conditions via uranyl photocatalysis to produce carboxylic acids, ketones, and alcohols, respectively. The accuracy of the stepwise oxygenation was ensured by the tunability of catalytic activity in uranyl photocatalysis, which was adjusted by solvents and additives demonstrated through Stern–Volmer analysis. Hydrogen atom transfer between the benzylic position and the uranyl catalyst facilitated oxygenation, further confirmed by kinetic studies. Considerably improved efficiency of flow operation demonstrated the potential for industrial synthetic application.

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

Farnesoid X receptor (FXR), a bile acid-activated nuclear receptor, regulates the metabolism of bile acid and lipids as well as maintains the stability of internal environment. FXR was considered as a therapeutic target of liver disorders, such as drug-induced liver injury, fatty liver and cholestasis. The previous reported FXR partial agonist 6 was a suitable lead compound in terms of its high potent and low molecular size, while the docking study of compound 6 suggested a large unoccupied hydrophobic pocket, which might be provided more possibility of structure-activity relationship (SAR) study. In this study, we have performed comprehensive SAR and molecular modeling studies based on lead compound 6. All of these efforts resulted in the identification of a novel series of FXR partial agonists. In this series, compound 41 revealed the best activity and strong interaction with binding pocket of FXR. Moreover, compound 41 protected mice against acetaminophen-induced hepatotoxicity by the regulation of FXR-related gene expression and improving antioxidant capacity. In summary, these results suggest that compound 41 is a promising FXR partial agonist suitable for further investigation.

COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION

The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and

Synthesis of a stable triformylmethane synthon and its scalable application to 7-acylamino-3-formylquinoline syntheses

Novel 2-iminiomethylvinamidinium trihalides were isolated as stable crystals and found to be useful triformylmethane synthons with non-deliquescent nature in air. They were easier to manufacture, handle, and store than the known 2-iminiomethylvinamidinium

8-benzamidochromen-4-one-2-carboxylic acids: Potent and selective agonists for the orphan G protein-coupled receptor GPR35

8-Amido-chromen-4-one-2-carboxylic acid derivatives were identified as novel agonists at the G protein-coupled orphan receptor GPR35. They were characterized by a β-arrestin recruitment assay and optimized to obtain agonists with nanomolar potency for the

An example of designed multiple ligands spanning protein classes: Dual MCH-1R antagonists/DPPIV inhibitors

A ligand-based approach to identify potential starting points for a dual MCH-1R antagonist/DPPIV inhibitor medicinal chemistry program was undertaken. Potential ligand pairs were identified by analysis of MCH-1R and DPPIV in vitro data. A highly targeted

Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3- aminomethylquinolines: Reducing human ether-a-go-go-related gene (hERG) associated liabilities

Recently, we discovered 3-aminomethylquinoline derivative 1, a selective, highly potent, centrally acting, and orally bioavailable human MCH receptor 1 (hMCHR1) antagonist, that inhibited food intake in F344 rats with diet-induced obesity (DIO). Subsequent investigation of 1 was discontinued because 1 showed potent hERG K+ channel inhibition in a patch-clamp study. To decrease hERG K+ channel inhibition, experiments with ligand-based drug designs based on 1 and a docking study were conducted. Replacement of the terminal p-fluorophenyl group with a cyclopropylmethoxy group, methyl group introduction on the benzylic carbon at the 3-position of the quinoline core, and employment of a [2-(acetylamino)ethyl]amino group as the amine portion eliminated hERG K+ channel inhibitory activity in a patch-clamp study, leading to the discovery of N-{3-[(1R)-1-{[2-(acetylamino)ethyl]amino} ethyl]-8-methylquinolin-7-yl}-4-(cyclopropylmethoxy)benzamide (R)-10h. The compound (R)-10h showed potent inhibitory activity against hMCHR1 and dose-dependently suppressed food intake in a 2-day study on DIO-F344 rats. Furthermore, practical chiral synthesis of (R)-10h was performed to determine the molecule's absolute configuration.

INHIBITORS OF ACETYL-COA CARBOXYLASE

The present invention relates to compounds that act as acetyl-CoA carboxylase (ACC) inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

HETEROCYCLIC COMPOUND

The present invention provides to a compound having melanin-concentrating hormone receptor antagonistic action and low toxicity, and useful as a agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound re

SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

It is an object of the present invention to provide a substituted propanamide derivative or a pharmacologically acceptable salt thereof that is useful as a prophylactic or therapeutic agent for a bone metabolic disease. The present invention relates to a pharmaceutical composition comprising a compound having General Formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein, R1 represents a C6-C10 aryl group that may be substituted by a group selected from Substituent Group α, for example; R2 represents a C6-C10aryl group that may be substituted by a group selected from Substituent Group α, for example; and X represents a hydroxyl group or a C1-C6 alkoxy group, for example].